Cell Culture-Based Quadrivalent Influenza Vaccine
Seasonal Influenza Prevention
Phase IIIActive
Key Facts
Indication
Seasonal Influenza Prevention
Phase
Phase III
Status
Active
About Hualan Biological Engineering
Hualan Biological Engineering's mission is to safeguard public health through the research, development, and large-scale manufacturing of high-quality vaccines and plasma-based therapeutics. The company has achieved a leading market share in China's influenza vaccine segment and built a formidable, asset-heavy business model anchored by its extensive plasma station network and established manufacturing platforms. Its strategy focuses on defending its core franchises while strategically investing in next-generation vaccine technologies, including cell culture-based production and conjugate vaccines, to drive future growth and enhance pandemic preparedness.
View full company profileTherapeutic Areas
Other Seasonal Influenza Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Seasonal Influenza Vaccines | CSL Seqirus | Approved/Commercial |
| Influenza mRNA Vaccine | Pfizer | Phase 3 |
| Quadrivalent Influenza Vaccine (QIV) | Hualan Biological Engineering | Marketed |
| Trivalent Influenza Vaccine (TIV) | Hualan Biological Engineering | Marketed |